John D. Imig
Professor
University of Arkansas for Medical Sciences
faculty
COP | College of Pharmacy
Research Areas
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
John D. Imig, a Professor in the College of Pharmacy at the University of Arkansas for Medical Sciences, conducts research focused on cardiovascular and kidney diseases. His work investigates the role of epoxyeicosatrienoic acids (EETs) and soluble epoxide hydrolase (sEH) in the progression of heart diseases and kidney injury. Imig has published extensively on these topics, with recent publications addressing multi-target approaches for metabolic and kidney diseases, as well as the impact of EETs on heart failure and cisplatin-induced nephrotoxicity.
His research is supported by federal grants, including two awards from the NIH totaling $698,479. One grant, for $514,673 from the National Institute of Diabetes and Digestive and Kidney Diseases, focuses on the role of endothelial epoxyeperoxidasome, kidney injury, and blood pressure regulation. The other, for $183,806 from the National Center for Advancing Translational Sciences, supports a CTSA postdoctoral T32 program at UAMS.
Imig's scholarship is recognized by his h-index of 72, with over 425 publications and 16,078 citations. He is a member of the ARA Academy and has been identified as a high-impact researcher. He maintains an active research group and collaborates with several researchers at the University of Arkansas for Medical Sciences, including Samaneh Goorani, Abdul H. Khan, and Abhishek Mishra.
Metrics
- h-index: 72
- Publications: 425
- Citations: 16,078
Selected Publications
- Editorial: New insights on vascular and metabolic diabetic complications (2026) DOI
- NF Erythroid 2-Related Factor 2 Peroxisome Proliferator-Activated Receptor-γ Crosstalk (2025) DOI
- EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage (2025) DOI
- Targeting p66Shc to restore KATP channel and renal microvascular responses in a preclinical model of diabetic nephropathy (2025) DOI
- Prevention of hypertension-induced renal vascular dysfunction through a p66Shc-targeted mechanism (2025) DOI
- 591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice (2025) DOI
- Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death (2025) DOI
- Hypertension: A Continuing Public Healthcare Issue (2024) DOI
- The Immune System in Nephrotoxicity (2024) DOI
- Kidney Hypoplasia Increases Kidney Injury following Reversal of Unilateral Ureteral Obstruction (2024) DOI
- O74 EPOXYEICOSATRIENOIC ACIDS ANALOGUE (EET-A) FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED HEART FAILURE WITH NEPHROTIC SYNDROME (2024) DOI
- Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats (2024) DOI
- Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4 (2024) DOI
- Novel compounds that target epoxyeicosanoids protect rat kidney epithelial cells in organ transplant solution during cold storage (2024) DOI
- Unraveling mechanisms underlying VEGF-TKI inhibitor related nephrotoxicity and protection by EET analogs: identifying key genes using RNA seq in mesangial cells (2024) DOI
ARA Academy 2022 ARA Scholar
Dr. Imig joined UAMS in 2022 from the Medical College of Wisconsin, where he directed the Drug Discovery Center. His research addresses conditions affecting the heart, metabolism, and kidneys. He maintains active NIH funding and has published approximately 250 articles and holds six U.S. patents with additional applications pending.
Policy Impact
Recruited from the Medical College of Wisconsin with active NIH funding, approximately 250 publications, and six U.S. patents — expanding Arkansas's drug discovery capacity.
Growth Areas
['Population Health Innovations & Clinical Research']
Federal Grants 2 $698,479 total
CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
Grants & Funding
- CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences NIH/National Center for Advancing Translational Sciences Principal Investigator
- Epoxyeicosanoids and Renal Vascular Function in Obesity &Hypertension NIH Principal Investigator
- Theophylline Prophylaxis during Hypothermia to Limit Neonatal Nephron Damage NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases - Pass Through: Medical College of Wisconsin Principal Investigator
- Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases Principal Investigator
- Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases Principal Investigator
- Role of p66Shc in Regulation of Microvascular Reactivity of Renal Blood Vessels NIH/Nat. Heart, Lung & Blood Institute - Pass Through: Medical College of Wisconsin Principal Investigator
- CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences NIH/National Center for Advancing Translational Sciences Principal Investigator
- OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY NIH Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics